# US 2025/0152683 A1 · Processes for producing compositions with improved safety profile having lipase activity and compositions suitable for pharmaceutical use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152683 A1
- Document ID: US20250152683A1
- Status: Published application
- Kind: A1
- Application number: 19/024,627
- Filed: 2025-01-16
- Published: 2025-05-15
- Earliest claimed: 2014-11-05
- Assignees: AbbVie Inc.
- Applicants: AbbVie Inc.
- Inventors: George SHLIEOUT; Christopher RUPP; Joerg BREITENBACH; Frauke-Regina RUEFFER; Frithjof SCZESNY
- Web page: https://patentgrep.com/patent/US20250152683A1

## CPC

- A61K 38/54: Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
- A61K 9/145: {with organic compounds}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 38/48: acting on peptide bonds (3.4)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C12Y 301/01003: Triacylglycerol lipase (3.1.1.3)
- C12Y 302/01: Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y 304/21004: Trypsin (3.4.21.4)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Processes are described for producing solid or semi-solid compositions, in particular solid oral compositions for pharmaceutical use, comprising treating an enzyme or enzyme-mixture with lipase-activity and a surfactant-component at defined process parameters. Said processes are suited for diminishing undesired biological contamination, e.g. viral contamination, of the said enzyme or enzyme-mixture while maintaining its desired biological activities, e.g. enzymatic activities. The process is suitable for industrial use. Also described are solid or semi-solid compositions comprising an enzyme or enzyme-mixture having lipase activity, a surfactant-component and a polymeric additive, optionally comprising further auxiliaries. Said compositions can preferably be obtained by the processes as described herein. Further described are pharmaceutical compositions comprising the solid or semi-solid compositions as described herein.

## Claims

### Claim 1

A process for the preparation of a solid or semi-solid composition, comprising processing a mixture, comprising
(a) 40-75% by weight of pancreatin and/or a pancreatin-containing mixture of digestive enzymes derived from a mammal;
(b) 10-50% by weight of a surfactant-component comprising
(i) at least one surfactant selected from polyethylene glycol-fatty acid monoesters; polyethylene glycol-fatty acid diesters; polyethylene glycol glycerol fatty acid esters; ethylene glycol alkyl ethers; polyethylene glycol glycerol fatty acid esters; polyethylene glycol alkyl ethers; oligoethylene glycol alkyl ethers; polyethylene glycol sterol ethers; polyethylene glycol sorbitan fatty acid esters; sugar esters; D-α-tocopheryl polyethylene glycol 1000 succinate; fatty acid amidoalkylbetaines with C2-C22 fatty acids; lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidylinositol, lysophosphatidic acid, lysophosphatidylserine, and mixtures of any of the foregoing,
(ii) optionally at least one co-surfactant selected from partial esters of glycerol, propylene glycol and/or polyglycerols with aliphatic carboxylic acids; esters of ethyl diglycol with aliphatic carboxylic acids; partial ethers of glycerol, propylene glycol, and/or polyglycerols with aliphatic alcohols; ethers of ethyl diglycol with aliphatic alcohols, mono or diesters of oligoethylene glycols with aliphatic carboxylic (fatty) acids and mixtures of any of the foregoing, and
(iii) optionally a lipophilic phase, selected from diglycerides of aliphatic carboxylic acids, triglycerides of aliphatic carboxylic acids and mixtures of any of the foregoing;
(c) 0-25% by weight of one or more pharmaceutically acceptable auxiliary agent(s),
and
(d) 0-35% by weight of a polymeric additive selected from hydrophilic polymers with a melting points or glass transition temperatures of 50-160° C.;
and wherein the % by weight of components (a), (b), (c) and (d) are weight to weight of the mixture for preparing a solid composition and add to 100% by weight for said mixture in each case;
by a method selected from melt granulation, melt pelletization and melt extrusion, in each case at a product temperature of 90-130° C. and for a time period of not less than 30 sec. and not exceeding 45 min.

### Claim 2 (depends on 1)

The process according to claim 1 wherein the surfactant-component (b) in the mixture for preparing a solid composition comprises:
(i) 2-90% by weight, relative to the surfactant-component, of at least one surfactant selected from (aa) non-ionic surfactants, comprising polyethylene glycol fatty acid mono- and/or di-esters with aliphatic C6-C22-carboxylic acids; polyethylene glycol glycerol fatty acid esters with aliphatic C6-C22-carboxylic acids; polyethylene glycol alkyl mono- and/or di-ethers with aliphatic Cia-C18-alcohols, oligoethylene glycol ethers with aliphatic C2-C18-alcohols; and mixtures of any of the foregoing, and (bb) ionic surfactants, comprising lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidylinositol, lysophosphatidic acid, lysophosphatidylserine; and mixtures of any of the foregoing, and mixtures of any of the foregoing surfactants from (aa) and (bb);
(ii) 5-60% by weight, relative to the surfactant-component, of at least one co-surfactant selected from mono-acylglycerides with aliphatic C6-C22-carboxylic acids, mono-ethers of glycerol with aliphatic C12-C22-alcohols, partial esters of propylenglycol with aliphatic C6-C22-carboxylic acids, partial esters of polyglycerol with aliphatic C6-C22-carboxylic acids, oligoethylene glycol monoesters with aliphatic C6-C22-carboxylic acids, oligoethylene glycol diesters with aliphatic C6-C22-carboxylic acids and mixtures of any of the foregoing and
(iii) 0-70% by weight, relative to the surfactant-component, of a lipophilic phase selected from di- and triacylglycerides with aliphatic C6-C22-carboxylic acids or mixtures of any of the foregoing,
wherein the percentages (i), (ii) and (iii) add to 100% by weight for the surfactant-component in each case.

### Claim 3 (depends on 1, 2)

The process according to any one of claim 1 or 2, wherein the mixture for preparing a solid composition comprises:
(a) 40-75%, preferably 40-70% by weight of the pancreatin and/or pancreatin containing mixture of digestive enzymes derived from a mammal;
(b) 10-50%, preferably 15-45% by weight of the surfactant-component,
(c) 0-15%, preferably 0-10% by weight of the one or more pharmaceutically acceptable auxiliary agent(s), and
(d) 5-35%, preferably 10-30% by weight of the polymeric additive;
and wherein the % by weight of components (a), (b), (c) and (d) are weight to weight of the mixture for preparing a solid composition and add to 100% by weight for said mixture in each case.

### Claim 4 (depends on 1, 2, 3)

The process according to any one of claims 1 to 3, wherein the mixture for preparing a solid composition is homogenized before processing and/or during processing.

### Claim 5 (depends on 1, 2, 3, 4)

A process according to any one of claims 1 to 4, wherein the polymeric additive (d) is selected from hydrophilic polymers with melting points or glass transition temperatures of 50-70° C., preferably of 50-65° C.

### Claim 6 (depends on 3, 4, 5)

A process according to any one of claims 3 to 5, wherein the weight ratio between the polymeric additive (d) and the surfactant-component (b) is between 0.4 (2:5) and 1.5 (3:2).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A process according to any one of claims 1 to 6, wherein component (a) is porcine pancreatin in an amount of 64%+/−6% by weight of the mixture and components (b), (d) and further optional auxiliary agents (c) together are present in an amount of 36%+/−6% by weight of the mixture.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A process according to any one of claims 1 to 7, wherein components (b) and (d) make up 30-42% by weight of the mixture and are composed of (b) semisynthetic lauroyl macrogol-32 glycerides on the basis of hydrogenated palm kernel oil having a melting point of about 42.5-47.5° C. and (d) polyethylene glycol 4000, in a ratio of 1:1 by weight, and further comprise (c) 100-150 ppm, preferably 150 ppm BHA, relative to the combined total weights of components (b) and (d).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The process according to any one of claims 1 to 8, wherein the processing method is melt extrusion and an extruder is used, selected from single-screw extruders, twin-screw-extruders, triple-screw extruders and planetary extruders.

### Claim 10 (depends on 9)

The process according to claim 9, wherein a twin-screw extruder, preferably a co-rotating twin screw extruder, is used.

### Claim 11 (depends on 9, 10)

The process according to claim 9 or 10, wherein the mixture for the preparation of a solid composition is processed at a product temperature of not less than 95° C. and not exceeding 125° C.′, for a time period of not less than 50 sec. and not exceeding 10 min.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The process according to any one of claims 1 to 8, wherein melt granulation is used as processing method, at a product temperature of not less than 90° C. and not exceeding 125° C., for a time period of not less than 180 sec. and not exceeding 30 min.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A process according to any one of claims 1 to 12, wherein the composition or extrudate formed is subsequently processed into granules, granulates, pellets, spheres, tablets and/or powders.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A pharmaceutical composition comprising a composition obtained by a process of anyone of claims 1 to 13, further optionally comprising one or more pharmaceutically acceptable excipients.

### Claim 15

A solid or semi-solid composition comprising:
(a) 40-75% by weight of the composition of pancreatin and/or a pancreatin containing mixture of digestive enzymes derived from a mammal;
(b) 10-50% by weight of the composition of a surfactant-component of
(i) 2-90% by weight, relative to the surfactant-component, of at least one surfactant selected from (aa) non-ionic surfactants, comprising polyethylene glycol fatty acid mono- and/or di-esters with aliphatic C6-C22-carboxylic acids; polyethylene glycol glycerol fatty acid esters with aliphatic C6-C22-carboxylic acids; polyethylene glycol alkyl mono- and/or di-ethers with aliphatic C: 2-C18-alcohols, oligoethylene glycol ethers with aliphatic C2-C18-alcohols; and mixtures of any of the foregoing, and (bb) ionic surfactants, comprising lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidylinositol, lysophosphatidic acid, lysophosphatidylserine; and mixtures of any of the foregoing, and mixtures of any of the foregoing surfactants from (aa) and (bb);
(ii) 5-60% by weight, relative to the surfactant-component, of at least one co-surfactant selected from mono-acylglycerides with aliphatic C6-C22-carboxylic acids, mono-ethers of glycerol with aliphatic C12-C22-alcohols, partial esters of propylenglycol with aliphatic C6-C22-carboxylic acids, partial esters of polyglycerol with aliphatic C6-C22-carboxylic acids, oligoethylene glycol monoesters with aliphatic C6-C22-carboxylic acids, oligoethylene glycol diesters with aliphatic C6-C22-carboxylic acids and mixtures of any of the foregoing and
(iii) 0-70% by weight, relative to the surfactant-component, of a lipophilic phase selected from di- and triacylglycerides with aliphatic C6-C22-carboxylic acids and/or mixtures of any of the foregoing;
wherein the percentages (i), (ii) and (iii) add to 100% by weight for the surfactant-component in each case;
(c) 0-25% by weight of the composition of one or more pharmaceutically acceptable auxiliary agent(s) and
(d) 5-50% by weight a polymeric additive selected from hydrophilic polymers with melting points or glass transition temperatures of 50-160° C.;
whereby the ratio of the polymeric additive (d) and the surfactant-component (b) is 0.4 (2:5) to 1.5 (3:2), preferably 1 (1:1), and whereby all weight percentages of components (a), (b), (c) and (d) in the composition add to 100% by weight.

### Claim 16 (depends on 15)

A composition according to claim 15, wherein the pancreatin and/or pancreatin containing mixture of digestive enzymes derived from a mammal (a) is porcine pancreatin.

### Claim 17 (depends on 15, 16)

A composition according to any one of claims 15 to 16, wherein the polymeric additive (d) is selected from hydrophilic polymers with melting points or glass transition temperatures of 50-70° C., preferably of from 50-65° C.

### Claim 18 (depends on 15, 16, 17)

A composition according to any one of claims 15 to 17, wherein the polymeric additive is selected from PEG 20000, PEG 4000 and Poloxamer 188.

### Claim 19 (depends on 15, 16, 17, 18)

A composition according to any one of claims 15 to 18, wherein the pancreatin and/or pancreatin containing mixture of digestive enzymes derived from a mammal (a) is present in an amount of 40-70%, 50-70%, 45-68%, 47-68% or 68% by weight of the composition.

### Claim 20 (depends on 15, 16, 17, 18, 19)

A composition according to any one of claims 15 to 19, wherein the surfactant-component (b) is present in an amount of 15-40%, 15-30%, 15-25%, 17.5-25% or 20% by weight of the composition.

### Claim 21 (depends on 15, 16, 17, 18, 19, 20)

A composition according to any one of claims 15 to 20, wherein the one or more pharmaceutically acceptable auxiliary agent(s) (c) is present in an amount of 0-20%, 0-10% or 0-5% by weight of the composition.

### Claim 22 (depends on 15, 16, 17, 18, 19, 20, 21)

A composition according to any one of claims 15 to 21, wherein the polymeric additive (d) is present in an amount of 5-35%, 10-30% or 15-25% by weight of the composition.

### Claim 23 (depends on 15, 16, 17, 18, 19, 20, 21, 22)

A composition according to any one of claims 15 to 22, wherein the surfactant-component (b) is selected from semisynthetic lauroyl macrogol-32 glycerides on the basis of hydrogenated palm kernel oil having a melting point of about 42.5-47.5° C. and comprising mono- and diesters of polyethylene glycol 1500 at about 72 wt.-%, mono-, di- and triglycerides of fatty acids 20 wt.-% and free polyethylene glycol 1500 about 8 wt.-%, (apportionment of the fatty acids: C8<15 wt.-%, C10<12 wt.-%, C12<30-50 wt.-%, C14 5-25 wt.-%, C16 4-25 wt.-% C8 5-35 wt.-%), free glycerol <wt.-3% and semisynthetic stearoyl macrogol-32 glycerides having a melting point of about 46-51° C. and comprising mono- and diesters of polyethylene glycol 1500 at about 72 wt.-%, mono-, di- and triglycerides of polyethylene glycol 1500 20 wt.-%, and free polyethylene glycol 1500 at about 8 wt.-% (apportionment of the fatty acids: C8<3 wt.-%, C10<3 wt.-%, C12<5 wt.-%, C14<5 wt.-%, C16 40-50 wt.-%, C18 48-58 wt.-%), free glycerol <3 wt.-%.

### Claim 24 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23)

A composition according to any one of claims 15 to 23, comprising
(a) porcine pancreatin in an amount of 58-70 wt.-%, preferably of 60-68% w/w
(b) Gelucire® 44/14 in an amount of 15-20% w/w and
(d) PEG 4000 in an amount of 15-25% w/w,
wherein the amounts of components (a), (b) and (d) in total amount to 100% w/w,

### Claim 25 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A pharmaceutical composition, comprising a composition according to any one of claims 15 to 24 and optionally conventional pharmaceutically acceptable excipients.

### Claim 26 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition according to any one of claims 14, 15-23 or the pharmaceutical composition according to claim 24 for the use in the prophylaxis or treatment of digestive disorders, pancreatic exocrine insufficiency, pancreatitis, cystic fibrosis, diabetes type I and/or diabetes type II.
